![](/img/cover-not-exists.png)
Early results of a multicenter phase 2 study: Weekly docetaxel and intermittent estramustin as combination chemotherapy in patients with hormone-refractory prostate cancer (HRPC)
U. Steiner, K. Miller, S. Machtens, B. Backhaus, M. SiegsmundVolume:
2
Year:
2003
Language:
english
DOI:
10.1016/s1569-9056(03)80098-2
File:
PDF, 226 KB
english, 2003